Targeting Foam Cells: A Dual-Function Nanoagent for Imaging and Treatment
Published: 16 Mar 2026
Author: Precedence Research
In a major advancement poised to change cardiovascular medicine, researchers have developed a hierarchical theranostic nanoagent designed for both multimodal imaging and targeted treatment of foam cells in atherosclerosis. This cutting-edge nanotechnology platform combines therapeutic and diagnostic capabilities at a molecular level, presenting a promising method to tackle the ongoing formation of atherosclerotic plaques, which are the leading causes of cardiovascular diseases worldwide. The study, led by Song, J., Kang, X., Yang, S., and others, and published in Nature Communications in 2026, highlights the potential of nanomedicine to enhance both disease visualization and treatment efficacy.
Improving Atherosclerosis Diagnosis and Therapy via Targeted Nanoagents
Atherosclerosis is characterized by lipid-rich foam cell accumulation in artery walls, leading to plaque formation, blood vessel blockage, and increased heart attack and stroke risk. Healthcare providers have struggled to detect vulnerable plaques early and provide targeted treatments that slow disease progression without systemic side effects. The new hierarchical theranostic nanoagent addresses these challenges by combining advanced imaging with targeted foam cell disruption, improving diagnostic accuracy and treatment efficacy.
According to Precedence Research, the Multimodal Imaging Market size accounted for USD 4.52 billion in 2025 and is predicted to increase from USD 4.75 billion in 2026 to approximately USD 7.43 billion by 2035, expanding at a CAGR of 5.10% from 2026 to 2035 due to increasing demand for technological advancements in hybrid systems, a rising geriatric population, and the expansion of healthcare infrastructure.
Its design features a structured architecture that integrates multiple functions within a single nanoparticle. The outer layer selectively targets foam cells through receptor-mediated endocytosis specific to macrophage-derived foam cells, ensuring therapeutic agents focus on diseased tissues while sparing healthy cells, thus minimizing off-target effects common in traditional drug treatments.
Smart Nanoparticle for Atherosclerotic Lesion Monitoring
The nanoagent features multimodal imaging capabilities with contrast agents for MRI, fluorescence imaging, and CT, enabling healthcare professionals to obtain high-resolution images of atherosclerotic lesions for early detection and precise localization of vulnerable plaques. These advanced imaging functions are crucial for real-time monitoring of disease progression and treatment responses.
The nanoagent also has a therapeutic role, delivering drugs that affect foam cell metabolism and induce apoptosis in these lipid-rich cells. Breaking down foam cells in plaques, it reduces inflammation and stabilizes plaques, lowering the risk of rupture and cardiovascular events. This dual-action approach exemplifies the integration of nanotechnology and molecular medicine in tackling complex diseases.
A recent report by Precedence Research highlights that the Multimodal Imaging Market is benefiting from the increasing prevalence of chronic diseases such as cancer, cardiovascular, and neurological diseases, necessitating early and accurate diagnosis.